购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • E1/E2/E3 Enzyme
    (2)
  • NEDD8
    (1)
  • VEGFR
    (1)
  • c-Met/HGFR
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 5日内发货
    (1)
  • 6-8周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "tas-4"的结果
筛选
搜索结果
TargetMol产品目录中 "

tas-4

"的结果
  • 抑制剂&激动剂
    5
    TargetMol | Inhibitors_Agonists
  • 化合物库
    1
    TargetMol | Compound_Libraries
  • 天然产物
    1
    TargetMol | Natural_Products
  • TAS-4
    TAS 4,TAS4
    T24854794544-99-3
    TAS-4 is a modulator of metabotropic glutamate receptor 4-positive allosteric.
    • ¥ 10600
    6-8周
    规格
    数量
  • TAS4464 hydrochloride
    T130901848959-11-4
    TAS4464 hydrochloride 是高效的、选择性的 NEDD8 活化酶 (NAE)抑制剂,其 IC50=0.955 nM。
    • ¥ 593
    In stock
    规格
    数量
  • TAS4464
    T13090L1848959-10-3
    TAS4464 is a highly potent and selective inhibitor of the NEDD8 activating enzyme (IC50: 0.955 nM).
    • ¥ 1270
    5日内发货
    规格
    数量
  • Pamufetinib
    TAS-115, H2OL3Q4XRD, 4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide
    T131081190836-34-0
    Pamufetinib (TAS-115) 是VEGFR 和c-Met HGFR 抑制剂,能够抑制 rVEGFR2 (IC50:30 nM)和 rMET (IC50:32 nM)的活性。
    • ¥ 328
    In stock
    规格
    数量
  • TAS-103
    T36695174634-08-3
    TAS-103 is a dual inhibitor of DNA topoisomerase I II, used for cancer research. TAS-103 is a dual inhibitor of DNA topoisomerase I II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells[1]. TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103[2]. TAS-103 inhibits the viability of HeLa cells, with an IC50 of 40 nM. TAS-103 (10 μM) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation[3]. TAS-103 (30 mg kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103[2]. [1]. Padget K, et al. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000 Sep 15;60(6):817-21. [2]. Shimizu K, et al. Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. Biol Pharm Bull. 2002 Oct;25(10):1385-7. [3]. Yoshida M, et al. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads. Mol Pharmacol. 2008 Mar;73(3):987-94. Epub 2007 Dec 18.
    • ¥ 1680
    待询
    规格
    数量